cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.12876445.v1
title: Additional file of Comparative genomics reveals diversity among xanthomonads infecting tomato and pepper

description: Additional file of Comparative genomics reveals diversity among xanthomonads infecting tomato and pepper
DOI: 10.25377/sussex.7969931.v1
title: Dataset for Everyday Childhoods research project. Saffron - Favourite Things Interview

description: This data was collected as part of Saffron's favourite things interview, carried out on the 03/01/2014 with Lucy Hadfield. This item belongs to the Everyday Childhoods project dataset. For more information, click on the project or collection link.
DOI: 10.6084/m9.figshare.7969940.v1
title: Understanding the cytotoxicity mitigation of 2-chlorophenothiazine/cyclodextrins through ‘<i>guest drug–host excipient’</i> encapsulation approach

description: Communicated by Ramaswamy H. Sarma
DOI: 10.25377/sussex.7969916
title: Dataset for Everyday Childhoods research project. Tempest - Day in a Life

description: This data was collected as part of Tempest's day in a life observation, carried out on the 28/08/2014 with Mary Jane Kehily. This item belongs to the Everyday Childhoods project dataset. For more information, click on the project or collection link.
DOI: 10.25377/sussex.7969898
title: Dataset for Everyday Childhoods research project. Tempest - Favourite Things Interview

description: This data was collected as part of Tempest's day in a life observation, carried out on the 28/08/2014 with Mary Jane Kehily. This item belongs to the Everyday Childhoods project dataset. For more information, click on the project or collection link.
DOI: 10.25377/sussex.7969916.v1
title: Dataset for Everyday Childhoods research project. Tempest - Day in a Life

description: This data was collected as part of Tempest's day in a life observation, carried out on the 28/08/2014 with Mary Jane Kehily. This item belongs to the Everyday Childhoods project dataset. For more information, click on the project or collection link.
DOI: 10.6084/m9.figshare.7969961.v1
title: Blooms for Bees dataset

description: Bumblebee sightings submitted to the Blooms for Bees project by members of the general public. Identifications checked by experts against photos submitted with the sighting records.
DOI: 10.25377/sussex.7969898.v1
title: Dataset for Everyday Childhoods research project. Tempest - Favourite Things Interview

description: This data was collected as part of Tempest's day in a life observation, carried out on the 28/08/2014 with Mary Jane Kehily. This item belongs to the Everyday Childhoods project dataset. For more information, click on the project or collection link.
DOI: 10.6084/m9.figshare.7969838
title: Supplementary Material for: Perceptions of Stroke and Associated Health-Care-Seeking Behavior in Northern Tanzania: A Community-Based Study

description: <b><i>Background:</i></b> Little is known about knowledge of stroke symptoms, perceptions of self-risk, and health-care-seeking behavior for stroke in East Africa. <b><i>Methods:</i></b> A 2-stage randomized population-based cluster survey with selection proportional to population size was performed in northern Tanzania. Self-identified household health-care decision makers were asked to list all symptoms of a stroke. They were further asked if they thought they had a chance of having a stroke and where they would present for care for stroke-like symptoms. A socioeconomic status score was derived via principal component analysis from 9 variables related to wealth. <b><i>Results:</i></b> Of 670 respondents, 184 (27.4%) knew a conventional stroke symptom and 51 (7.6%) thought they had a chance of having a stroke. Females were less likely to perceive themselves to be at risk than males (OR 0.49, 95% CI 0.28–0.89, <i>p</i> = 0.014). Of respondents, 558 (88.3%) stated they would present to a hospital for stroke-like symptoms. Preference for a hospital was not associated with knowledge of stroke symptoms or perception of self-risk but was associated with a higher socioeconomic status score (<i>p</i> &lt; 0.001). <b><i>Conclusions:</i></b> Knowledge of stroke symptoms and perception of self-risk are low in northern Tanzania, but most residents would present to a hospital for stroke-like symptoms.
DOI: 10.1285/i22390359v36p5
title: Studi - Articles
DOI: 10.6084/m9.figshare.7969763
title: Genome annotation - Drosophila simulans M252 strain

description: MAKER2 annotation of a <i>D. simulans</i> genome (M252 strain). The annotation contains 13,422 genes and 18,301 transcripts. It was performed after repeat masking by combining ab initio predictions from Augustus, RNAseq data from Palmieri <i>et al</i>. (2015, Molecular Ecology Resources), protein sequence data from <i>D. melanogaster</i> & <i>D. simulans</i> and a de novo transcriptome obtained by PacBio full length sequencing of transcripts (IsoSeq pipeline, ~10Gb of raw data).All details are available in the publication referenced below.
DOI: 10.6084/m9.figshare.7969736
title: Supplementary Material for: Successful Reperfusion with Endovascular Therapy Has Beneficial Effects on Long-Term Outcome Beyond 90 Days

description: <b><i>Background and Purpose:</i></b> Recent studies have demonstrated that endovascular reperfusion therapy improves clinical outcomes at 90 days after ischemic stroke. However, the effects on long-term outcomes are not well known. We hypothesized that successful reperfusion might be associated with long-term improvement beyond 90 days after endovascular therapy. To assess the long-term effects beyond 90 days, we analyzed the association of successful reperfusion with a temporal change in modified Rankin Scale (mRS) score from 90 days to 1 year after endovascular therapy. <b><i>Methods:</i></b> We retrospectively analyzed a database of consecutive patients with acute ischemic stroke who received endovascular therapy between April 2006 and March 2016 at 4 centers. We compared the incidences of improvement and deterioration in patients with successful reperfusion (i.e., modified thrombolysis in cerebral infarction score of 2b or 3) with those in patients with unsuccessful reperfusion. We defined improvement and deterioration as decrease and increase on the mRS score by 1 point or more from 90 days to 1 year after endovascular therapy respectively. <b><i>Results:</i></b> A total of 268 patients were included in the current study. The rate of patients with improvement tended to be higher in patients with successful reperfusion than in patients with unsuccessful reperfusion (20% [34/167 patients] vs. 12% [12/101], <i>p</i> = 0.07). The rate of patients with deterioration was lower in patients with successful reperfusion than in patients with unsuccessful reperfusion (25% [42/167] vs. 42% [42/101], <i>p</i> &lt; 0.01). After adjustment for confounders, successful reperfusion was associated with improvement (adjusted OR 2.65; 95% CI 1.23–5.73; <i>p</i> &lt; 0.05) and deterioration (adjusted OR 0.33; 95% CI 0.18–0.62; <i>p</i> &lt; 0.01), independent of the 90-day mRS score. <b><i>Conclusions:</i></b> Successful reperfusion has further beneficial legacy effects on long-term outcomes beyond 90 days after stroke.
DOI: 10.6084/m9.figshare.7969763.v1
title: Genome annotation - Drosophila simulans M252 strain

description: MAKER2 annotation of a <i>D. simulans</i> genome (M252 strain). The annotation contains 13,422 genes and 18,301 transcripts. It was performed after repeat masking by combining ab initio predictions from Augustus, RNAseq data from Palmieri <i>et al</i>. (2015, Molecular Ecology Resources), protein sequence data from <i>D. melanogaster</i> & <i>D. simulans</i> and a de novo transcriptome obtained by PacBio full length sequencing of transcripts (IsoSeq pipeline, ~10Gb of raw data).All details are available in the publication referenced below.
DOI: 10.6084/m9.figshare.7969736.v1
title: Supplementary Material for: Successful Reperfusion with Endovascular Therapy Has Beneficial Effects on Long-Term Outcome Beyond 90 Days

description: <b><i>Background and Purpose:</i></b> Recent studies have demonstrated that endovascular reperfusion therapy improves clinical outcomes at 90 days after ischemic stroke. However, the effects on long-term outcomes are not well known. We hypothesized that successful reperfusion might be associated with long-term improvement beyond 90 days after endovascular therapy. To assess the long-term effects beyond 90 days, we analyzed the association of successful reperfusion with a temporal change in modified Rankin Scale (mRS) score from 90 days to 1 year after endovascular therapy. <b><i>Methods:</i></b> We retrospectively analyzed a database of consecutive patients with acute ischemic stroke who received endovascular therapy between April 2006 and March 2016 at 4 centers. We compared the incidences of improvement and deterioration in patients with successful reperfusion (i.e., modified thrombolysis in cerebral infarction score of 2b or 3) with those in patients with unsuccessful reperfusion. We defined improvement and deterioration as decrease and increase on the mRS score by 1 point or more from 90 days to 1 year after endovascular therapy respectively. <b><i>Results:</i></b> A total of 268 patients were included in the current study. The rate of patients with improvement tended to be higher in patients with successful reperfusion than in patients with unsuccessful reperfusion (20% [34/167 patients] vs. 12% [12/101], <i>p</i> = 0.07). The rate of patients with deterioration was lower in patients with successful reperfusion than in patients with unsuccessful reperfusion (25% [42/167] vs. 42% [42/101], <i>p</i> &lt; 0.01). After adjustment for confounders, successful reperfusion was associated with improvement (adjusted OR 2.65; 95% CI 1.23–5.73; <i>p</i> &lt; 0.05) and deterioration (adjusted OR 0.33; 95% CI 0.18–0.62; <i>p</i> &lt; 0.01), independent of the 90-day mRS score. <b><i>Conclusions:</i></b> Successful reperfusion has further beneficial legacy effects on long-term outcomes beyond 90 days after stroke.
DOI: 10.6084/m9.figshare.7969715
title: Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis

description: <i>Background</i>: Plasma creatinine has been described as a prognostic biomarker for Amyotrophic Lateral Sclerosis (ALS), but with conflicting results in the literature. We performed a systematic review followed by a meta-analysis to address this question. <i>Methods</i>: We performed a systematic review of Pubmed, Embase and Cochrane databases and retrieved 14 distinct cohorts (19 studies) reporting results regarding the relationship between plasma creatinine and a clinical marker for ALS progression, notably ALSFRS (ALS Functional Rating Scale) and survival. <i>Results</i>: For baseline plasma creatinine, mortality risk was 28% lower when creatinine was higher than 88.4 µmol/L (hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.58 to 0.88; <i>p</i> = 0.0003) and was 25% lower if creatinine was above versus below the median (HR: 0.75; 95% CI: 0.63 to 0.89; <i>p</i> = 0.0008). We found a significant positive correlation between plasma creatinine at baseline and functional score, and between creatinine decline and functional score decline (<i>p</i> p = 0.033). The overall quality of the studies was low mainly due to potential attrition bias, and several studies did not report analyzable results raising concern regarding a potential reporting bias. <i>Conclusions</i>: Plasma creatinine seems to be a promising prognostic biomarker for ALS. However, new studies with sound methodology and standardized criteria for the evaluation of ALS progression should be conducted to validate plasma creatinine as a clinical biomarker for ALS prognosis.
DOI: 10.6084/m9.figshare.7969703
title: Genome assembly - Drosophila simulans M252 strain

description: Fasta file of a <i>D. simulans</i> genome assembly (M252 strain, Madagascar). The genome was sequenced using PacBio (8 Gb, ~ 50x coverage) and assemblies obtained with Canu & Falcon were merged after polishing (Quiver and Pilon, two iterations each). The merged assembly was polished again (Quiver and Pilon, two iterations each) before anchoring contigs on the <i>D. melanogaster</i> r6 genome. The total genome size is 127.32 Mb, among which 115.08 Mb are anchored on <i>D. melanogaster</i> main chromosome arms. All details are available in the publication.
DOI: 10.6084/m9.figshare.12876448
title: Additional file 10 of Comparative genomics reveals diversity among xanthomonads infecting tomato and pepper

description: Additional file 10:Table S10: Genes unique to Xg. Genes of special interest are highlighted in red and yellow. (XLSX 36 KB)
DOI: 10.6084/m9.figshare.7969700
title: Revisiting the Relationship between WIC Participation and Breastfeeding: An Instrumental Variable Approach

description: Our primary data source is the National Immunization Surveys (NIS). NIS is a national annual cross-sectional population-based survey sponsored and conducted by the National Center for Immunization and Respiratory Diseases (NCIRD) of the Centers for Disease Control and Prevention (CDC). It is an annual, telephone-based survey by interviewing with parents or guardians in all 50 states, the District of Columbia, and some U.S. territories to monitor vaccination coverage among children 19–35 months and teens 13–17 years. The NIS provides nationally, state, and locally representative estimate of vaccination coverage among children and teenagers. We used only the NIS-child data in this study, which contains information on sociodemographic and health insurance information for 19 - 35 months children as well as their mothers’ WIC participation status. NIS-child also reports the child’s breastfeeding information. NIS-child is the data used by CDC to produce the annual national Breastfeeding Report Card, which includes the national- and state-level breastfeeding rates. Aiming to be comparable and consistent with the results of the CDC Breastfeeding Report Card, we included the data from 50 states and D.C. and combined two survey years data as one cohort by the year of child-birth following the methods used in the CDC NIS data analysis guide. Data for this study were derived from the 2006-2016 NIS-child public use data, which does not provide the survey child’s birth month and year information but includes the child’s age group information (age groups: 19-23 months, 24-29 months, and 30-35 months respectively). We used the child’s age group information to infer their birth year. For example, children aged 19-23 months in the 2015 NIS-child survey year represent the child from January 2014 to May 2014. Similarly, children aged 24 months or older in the 2016 NIS-child survey data can also be born in 2014. Therefore, we combined these children from the 2015 and 2016 NIS-child survey data to create a 2014 NIS-child birth cohort. In this study, we created the birth cohorts of 2005 to 2014 by using the 2006-2016 NIS-child survey data. To ensure that these birth cohorts consistent with the cohorts in the CDC’s breastfeeding report card, we replicated the ever-breastfeeding rates, which were essentially the same as in the published report.
DOI: 10.6084/m9.figshare.7969703.v2
title: Genome assembly - Drosophila simulans M252 strain

description: Fasta file of a <i>D. simulans</i> genome assembly (M252 strain, Madagascar). The genome was sequenced using PacBio (8 Gb, ~ 50x coverage) and assemblies obtained with Canu & Falcon were merged after polishing (Quiver and Pilon, two iterations each). The merged assembly was polished again (Quiver and Pilon, two iterations each) before anchoring contigs on the <i>D. melanogaster</i> r6 genome. The total genome size is 127.32 Mb, among which 115.08 Mb are anchored on <i>D. melanogaster</i> main chromosome arms. All details are available in the publication.
DOI: 10.6084/m9.figshare.7969715.v2
title: Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis

description: <i>Background</i>: Plasma creatinine has been described as a prognostic biomarker for Amyotrophic Lateral Sclerosis (ALS), but with conflicting results in the literature. We performed a systematic review followed by a meta-analysis to address this question. <i>Methods</i>: We performed a systematic review of Pubmed, Embase and Cochrane databases and retrieved 14 distinct cohorts (19 studies) reporting results regarding the relationship between plasma creatinine and a clinical marker for ALS progression, notably ALSFRS (ALS Functional Rating Scale) and survival. <i>Results</i>: For baseline plasma creatinine, mortality risk was 28% lower when creatinine was higher than 88.4 µmol/L (hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.58 to 0.88; <i>p</i> = 0.0003) and was 25% lower if creatinine was above versus below the median (HR: 0.75; 95% CI: 0.63 to 0.89; <i>p</i> = 0.0008). We found a significant positive correlation between plasma creatinine at baseline and functional score, and between creatinine decline and functional score decline (<i>p</i> p = 0.033). The overall quality of the studies was low mainly due to potential attrition bias, and several studies did not report analyzable results raising concern regarding a potential reporting bias. <i>Conclusions</i>: Plasma creatinine seems to be a promising prognostic biomarker for ALS. However, new studies with sound methodology and standardized criteria for the evaluation of ALS progression should be conducted to validate plasma creatinine as a clinical biomarker for ALS prognosis.
DOI: 10.6084/m9.figshare.12876448.v1
title: Additional file 10 of Comparative genomics reveals diversity among xanthomonads infecting tomato and pepper

description: Additional file 10:Table S10: Genes unique to Xg. Genes of special interest are highlighted in red and yellow. (XLSX 36 KB)
DOI: 10.6084/m9.figshare.7969703.v1
title: Drosophila simulans genome assembly - M252 strain

description: Final fasta file of the merged (Canu & Falcon) and polished (Quiver & Pilon) D. simulans genome assembly (M252 strain). The total genome size is 127.32 Mb. All details are available in the publication (https://doi.org/10.1101/425710).
DOI: 10.6084/m9.figshare.7969715.v1
title: Plasma creatinine and amyotrophic lateral sclerosis prognosis: a systematic review and meta-analysis

description: <i>Background</i>: Plasma creatinine has been described as a prognostic biomarker for Amyotrophic Lateral Sclerosis (ALS), but with conflicting results in the literature. We performed a systematic review followed by a meta-analysis to address this question. <i>Methods</i>: We performed a systematic review of Pubmed, Embase and Cochrane databases and retrieved 14 distinct cohorts (19 studies) reporting results regarding the relationship between plasma creatinine and a clinical marker for ALS progression, notably ALSFRS (ALS Functional Rating Scale) and survival. <i>Results</i>: For baseline plasma creatinine, mortality risk was 28% lower when creatinine was higher than 88.4 µmol/L (hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.58 to 0.88; <i>p</i> = 0.0003) and was 25% lower if creatinine was above versus below the median (HR: 0.75; 95% CI: 0.63 to 0.89; <i>p</i> = 0.0008). We found a significant positive correlation between plasma creatinine at baseline and functional score, and between creatinine decline and functional score decline (<i>p</i> p = 0.033). The overall quality of the studies was low mainly due to potential attrition bias, and several studies did not report analyzable results raising concern regarding a potential reporting bias. <i>Conclusions</i>: Plasma creatinine seems to be a promising prognostic biomarker for ALS. However, new studies with sound methodology and standardized criteria for the evaluation of ALS progression should be conducted to validate plasma creatinine as a clinical biomarker for ALS prognosis.
DOI: 10.6084/m9.figshare.7969685
title: Development, characterization, swelling, and network parameters of amino acid grafted guar gum based pH responsive polymeric hydrogels

description: This study includes the synthesis of graft copolymer (GG-g-PAPA) from N-Acryloyl-L-phenylalanine (APA) and guar gum through free radical polymerization. Then, the novel pH sensitive GG-g-PAPA-<i>cl</i>-(PHEA-<i>co</i>-PAMPS) [GGAH] polymeric hydrogels were synthesized by employing free radical cross-linking polymerization using graft copolymer, 2-acrylamido-2-methyl-1-propanesulfonic acid (AMPS), and 2-hydroxy ethyl acrylate (HEA). The GGAH hydrogels were characterized using FTIR and SEM. Swelling studies of GGAH hydrogels were performed in distilled water, pH 1.2, and pH 7.4 solutions. The network and swelling kinetic parameters of GGAH hydrogels are also calculated.
DOI: 10.6084/m9.figshare.7969646
title: Supplementary Material for: Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)

description: <b><i>Background/Aims:</i></b> To assess health-related quality of life (HRQoL), treatment patterns, and clinical outcomes of adult (≥18 years) patients with advanced (unresectable or metastatic) pancreatic neuroendocrine neoplasms (PanNENs) treated with everolimus in routine clinical practice. <b><i>Methods:</i></b> In a prospective, non-interventional, multi-center study patients administered at least one 10 mg dose of everolimus were evaluated for change in HRQoL (EORTC QLQ-C30 Global Health Status scale) from baseline after 6 months treatment (primary endpoint). Secondary endpoints included disease-specific HRQoL measures (EORTC QLQ-G.I.NET21), clinical outcomes, everolimus treatment patterns, and safety. <b><i>Results:</i></b> Forty-eight patients were recruited (between August 2013 and March 2015); the median treatment duration was 27.8 months. EORTC QLQ-C30 Global Health score was not significantly different from baseline after 6 months of treatment (mean difference –1.9 points, <i>p</i> = 0.660, <i>n</i> = 30). In pairwise analyses, the only significant changes in HRQoL from baseline were for EORTC QLQ-C30 physical functioning score at month 3 (adjusted mean difference –8.8 points, <i>p</i> = 0.002, <i>n</i> = 36) and the EORTC QLQ-G.I.NET21 disease-related worries scores at months 1 and 2 (adjusted mean differences: –11.5 points [<i>p</i> = 0.001, <i>n</i> = 44] and –8.8 points [<i>p</i> = 0.017, <i>n</i> = 43], respectively). Disease progression or death was recorded in 44.4% (<i>n</i> = 20/45) patients during follow-up; median progression-free survival was 25.1 months and the cumulative survival rate at 3 years was 71%. No new safety signals were detected. <b><i>Conclusions:</i></b> The OBLIQUE study demonstrates that HRQoL is maintained in patients with PanNENs during treatment with everolimus in a UK real-world setting. This study adds to the limited HRQoL data available in this patient group.